JP2014516339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516339A5 JP2014516339A5 JP2013556894A JP2013556894A JP2014516339A5 JP 2014516339 A5 JP2014516339 A5 JP 2014516339A5 JP 2013556894 A JP2013556894 A JP 2013556894A JP 2013556894 A JP2013556894 A JP 2013556894A JP 2014516339 A5 JP2014516339 A5 JP 2014516339A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- formulated
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 14
- 241000222122 Candida albicans Species 0.000 claims description 7
- 206010017533 Fungal infection Diseases 0.000 claims description 7
- 208000031888 Mycoses Diseases 0.000 claims description 7
- 201000003984 candidiasis Diseases 0.000 claims description 7
- 208000002474 Tinea Diseases 0.000 claims description 6
- 241000893966 Trichophyton verrucosum Species 0.000 claims description 6
- 206010007134 Candida infections Diseases 0.000 claims description 5
- 241000228245 Aspergillus niger Species 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 208000010195 Onychomycosis Diseases 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 201000005882 tinea unguium Diseases 0.000 claims description 4
- 150000003841 chloride salts Chemical class 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 201000002909 Aspergillosis Diseases 0.000 claims description 2
- 241000131314 Aspergillus candidus Species 0.000 claims description 2
- 241000228193 Aspergillus clavatus Species 0.000 claims description 2
- 241000228197 Aspergillus flavus Species 0.000 claims description 2
- 241001225321 Aspergillus fumigatus Species 0.000 claims description 2
- 208000036641 Aspergillus infections Diseases 0.000 claims description 2
- 241000122824 Aspergillus ochraceus Species 0.000 claims description 2
- 241001465318 Aspergillus terreus Species 0.000 claims description 2
- 241000222173 Candida parapsilosis Species 0.000 claims description 2
- 241000222178 Candida tropicalis Species 0.000 claims description 2
- 240000002355 Celtis tournefortii var. glabrata Species 0.000 claims description 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
- 241001508813 Clavispora lusitaniae Species 0.000 claims description 2
- 241000223205 Coccidioides immitis Species 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 201000002563 Histoplasmosis Diseases 0.000 claims description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 2
- 241000235048 Meyerozyma guilliermondii Species 0.000 claims description 2
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims description 2
- 206010030154 Oesophageal candidiasis Diseases 0.000 claims description 2
- 206010033767 Paracoccidioides infections Diseases 0.000 claims description 2
- 201000000301 Paracoccidioidomycosis Diseases 0.000 claims description 2
- 241000235645 Pichia kudriavzevii Species 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010041736 Sporotrichosis Diseases 0.000 claims description 2
- 206010042938 Systemic candida Diseases 0.000 claims description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims description 2
- 206010061418 Zygomycosis Diseases 0.000 claims description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 claims description 2
- 208000037815 bloodstream infection Diseases 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
- 201000003486 coccidioidomycosis Diseases 0.000 claims description 2
- 201000005655 esophageal candidiasis Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000007524 mucormycosis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000026435 phlegm Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 159000000021 acetate salts Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 0 CC1=C(*)N=NC1[Rn] Chemical compound CC1=C(*)N=NC1[Rn] 0.000 description 11
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448807P | 2011-03-03 | 2011-03-03 | |
| US61/448,807 | 2011-03-03 | ||
| PCT/US2012/027451 WO2012119065A2 (en) | 2011-03-03 | 2012-03-02 | Antifungal agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178029A Division JP6111447B2 (ja) | 2011-03-03 | 2015-09-10 | 抗真菌薬及びそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516339A JP2014516339A (ja) | 2014-07-10 |
| JP2014516339A5 true JP2014516339A5 (cg-RX-API-DMAC7.html) | 2015-05-14 |
| JP5809296B2 JP5809296B2 (ja) | 2015-11-10 |
Family
ID=46758514
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013556894A Active JP5809296B2 (ja) | 2011-03-03 | 2012-03-02 | 抗真菌薬及びそれらの使用 |
| JP2015178029A Active JP6111447B2 (ja) | 2011-03-03 | 2015-09-10 | 抗真菌薬及びそれらの使用 |
| JP2017026954A Active JP6302108B2 (ja) | 2011-03-03 | 2017-02-16 | 抗真菌薬及びそれらの使用 |
| JP2018036159A Pending JP2018118977A (ja) | 2011-03-03 | 2018-03-01 | 抗真菌薬及びそれらの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178029A Active JP6111447B2 (ja) | 2011-03-03 | 2015-09-10 | 抗真菌薬及びそれらの使用 |
| JP2017026954A Active JP6302108B2 (ja) | 2011-03-03 | 2017-02-16 | 抗真菌薬及びそれらの使用 |
| JP2018036159A Pending JP2018118977A (ja) | 2011-03-03 | 2018-03-01 | 抗真菌薬及びそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US8722619B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3192803B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP5809296B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN106279369B (cg-RX-API-DMAC7.html) |
| CA (2) | CA3053850A1 (cg-RX-API-DMAC7.html) |
| CY (2) | CY1119709T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2680873T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2645074T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FIC20240022I1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR24C1027I2 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20171579T8 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE036778T2 (cg-RX-API-DMAC7.html) |
| LT (2) | LT2680873T (cg-RX-API-DMAC7.html) |
| NL (1) | NL301280I2 (cg-RX-API-DMAC7.html) |
| NO (1) | NO2680873T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2680873T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2680873T (cg-RX-API-DMAC7.html) |
| RS (1) | RS56426B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2680873T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT201700460T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012119065A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2680873T3 (cg-RX-API-DMAC7.html) | 2011-03-03 | 2018-01-06 | ||
| HUE063336T2 (hu) | 2012-03-19 | 2024-01-28 | Cidara Therapeutics Inc | Adagolási rend echinokandin osztályba tartozó vegyületekhez |
| WO2015035102A2 (en) * | 2013-09-04 | 2015-03-12 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of fungal infections |
| AU2015253484A1 (en) * | 2014-04-28 | 2016-10-06 | University Of Central Florida Research Foundation, Inc. | Compositions, methods of making a composition, and methods of use |
| WO2016201283A1 (en) * | 2015-06-12 | 2016-12-15 | Cidara Therapeutics, Inc. | Antifungal agents |
| WO2017049102A1 (en) * | 2015-09-16 | 2017-03-23 | Cidara Therapeutics, Inc. | Methods for treating fungal infections |
| CN106674333B (zh) * | 2015-11-06 | 2020-10-27 | 博瑞生物医药（苏州）股份有限公司 | 一种环肽类抗真菌化合物及其制备方法 |
| HK1258533A1 (zh) | 2016-01-08 | 2019-11-15 | Cidara Therapeutics, Inc. | 防止和治疗肺孢子虫感染的方法 |
| MA43825A (fr) | 2016-03-16 | 2021-04-07 | Cidara Therapeutics Inc | Schémas posologiques pour le traitement d'infections fongiques |
| EP3512539A4 (en) | 2016-09-13 | 2020-07-29 | Prothera Biologics, Inc. | METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS |
| US20210002346A1 (en) * | 2016-11-29 | 2021-01-07 | Cidara Therapeutics, Inc | Methods for preventing fungal infections |
| EP3577129A1 (en) * | 2017-01-31 | 2019-12-11 | Cidara Therapeutics, Inc. | Methods for treating fungal infections |
| CN110691973B (zh) | 2017-04-25 | 2024-11-29 | 普罗瑟拉生物公司 | 用于定量间α抑制剂蛋白的方法 |
| CA3069423C (en) | 2017-07-12 | 2025-04-15 | Napp Pharmaceutical Group Limited | Formulations for the treatment of fungal infections |
| WO2019241626A1 (en) * | 2018-06-15 | 2019-12-19 | Cidara Therapeutics, Inc. | Synthesis of echinocandin antifungal agent |
| WO2020086931A1 (en) * | 2018-10-25 | 2020-04-30 | Cidara Therapeutics, Inc. | Polymorph of echinocandin antifungal agent |
| TWI891685B (zh) | 2019-12-06 | 2025-08-01 | 大陸商上海森輝醫藥有限公司 | 棘白菌素類似物及其製備方法 |
| US20240262866A1 (en) | 2021-06-03 | 2024-08-08 | Shanghai Senhui Medicine Co., Ltd. | Method for preparing anidulafungin derivative |
| CN115850383A (zh) * | 2022-12-15 | 2023-03-28 | 江苏九阳生物制药有限公司 | 一种雷扎芬净纯化方法 |
| CN116903706B (zh) * | 2023-06-13 | 2024-05-17 | 深圳市祥根生物有限公司 | 一种棘白菌素类药物及其制备方法和用途 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427660A (en) | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
| US5166135A (en) | 1988-09-12 | 1992-11-24 | Merck & Company, Inc. | Method for the control of pneumocystis carinii |
| US6030944A (en) * | 1991-10-01 | 2000-02-29 | Merck & Co., Inc. | Cyclohexapeptidyl bisamine compounds |
| US5399552A (en) | 1991-10-17 | 1995-03-21 | Merck & Co, Inc | Antibiotic peptides bearing aminoalkylthioether moieties |
| US5378804A (en) | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US6268338B1 (en) | 1993-04-30 | 2001-07-31 | Merck & Co., Inc. | Cyclohexapeptidyl amine compounds |
| WO1994025045A1 (en) | 1993-05-04 | 1994-11-10 | Merck & Co., Inc. | Cyclohexapeptidyl aminoalkyl ethers |
| US5948753A (en) | 1993-05-04 | 1999-09-07 | Merck & Co., Inc. | Cyclohexapeptidyl propanolamine compounds |
| WO1995008341A1 (en) * | 1993-09-22 | 1995-03-30 | Merck & Co., Inc. | Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use |
| US5541160A (en) * | 1994-04-04 | 1996-07-30 | Merck & Co., Inc. | Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use |
| US5514651A (en) | 1994-09-16 | 1996-05-07 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| US5516756A (en) | 1994-10-31 | 1996-05-14 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
| ES2162039T3 (es) | 1995-01-26 | 2001-12-16 | Merck & Co Inc | Nuevos ciclohexapeptidos antifungicos. |
| US5652213A (en) * | 1995-05-26 | 1997-07-29 | Eli Lilly And Company | Cyclic peptide antifungal agents |
| PE63998A1 (es) | 1996-04-19 | 1998-10-30 | Merck & Co Inc | Composiciones anti-fungosas |
| US6069126A (en) | 1996-09-12 | 2000-05-30 | Merck & Co., Inc. | Antifungal combination therapy |
| US6506726B1 (en) * | 1998-12-09 | 2003-01-14 | Eli Lilly And Company | Purification of Echinocandin cyclopeptide compounds |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| KR20010112302A (ko) | 1999-03-03 | 2001-12-20 | 피터 지. 스트링거 | 제약학적 경구용 ｅｃｂ 조제물 및 조성물의 제조 방법 |
| HK1040062A1 (zh) | 1999-03-03 | 2002-05-24 | Eli Lilly And Company | 含有成胶束表面活性剂的棘白菌素药物配方 |
| US6309622B1 (en) | 1999-03-26 | 2001-10-30 | Protech Professional Products, Inc. | Antimicrobial denture cleansing compositions |
| EP1172105A4 (en) | 1999-04-16 | 2002-09-04 | Fujisawa Pharmaceutical Co | ANTIFUNGAL COMPOSITIONS |
| US6610822B2 (en) | 2000-09-01 | 2003-08-26 | Merck & Co., Inc. | Purification process |
| HU0104790D0 (en) | 2001-11-08 | 2002-01-28 | Human Rt | Pharmaceutical combinations for topical application |
| US6991800B2 (en) | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| US20060276339A1 (en) | 2002-10-16 | 2006-12-07 | Windsor J B | Methods and compositions for increasing the efficacy of biologically-active ingredients |
| US6913759B2 (en) | 2003-03-11 | 2005-07-05 | Curatek Pharmaceuticals Holding, Inc. | Gel composition and method for treatment of vaginal infections |
| US7452861B2 (en) * | 2003-07-22 | 2008-11-18 | Theravance, Inc. | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent |
| US20060140990A1 (en) | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
| EP1907588B1 (en) | 2005-07-26 | 2013-06-05 | The University of Medicine and Dentistry of New Jersey | Assays for resistance to echinocandin-class drugs |
| WO2007113386A1 (en) * | 2006-03-31 | 2007-10-11 | Karyon-Ctt Ltd | Peptide conjugates |
| GB0702020D0 (en) | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| US20090238867A1 (en) | 2007-12-13 | 2009-09-24 | Scott Jenkins | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same |
| US20100009009A1 (en) | 2008-07-10 | 2010-01-14 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
| GB0817121D0 (en) | 2008-09-18 | 2008-10-29 | Univ St Andrews | Anti-fungal therapy |
| DK2400951T3 (en) | 2009-02-25 | 2018-12-03 | Mayne Pharma Llc | TOPICAL FOAM COMPOSITION |
| US9006391B2 (en) * | 2009-05-07 | 2015-04-14 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Method for the preparation of cyclopeptides |
| US20110207828A1 (en) | 2009-08-26 | 2011-08-25 | Miller Guy M | Methods for the prevention and treatment of cerebral ischemia |
| EP2470190A4 (en) | 2009-08-27 | 2013-07-17 | Seachaid Pharmaceuticals Inc | ECHINOCANDINDERIVATE |
| EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
| NO2680873T3 (cg-RX-API-DMAC7.html) | 2011-03-03 | 2018-01-06 | ||
| EP2739652B1 (en) | 2011-08-04 | 2017-04-05 | Medizinische Universität Innsbruck | Cahgt1p inhibitors for use in the treatment of candidiasis |
| US8829053B2 (en) | 2011-12-07 | 2014-09-09 | Rochal Industries Llp | Biocidal compositions and methods of using the same |
| HUE063336T2 (hu) | 2012-03-19 | 2024-01-28 | Cidara Therapeutics Inc | Adagolási rend echinokandin osztályba tartozó vegyületekhez |
| CN102766198A (zh) | 2012-05-04 | 2012-11-07 | 中国人民解放军第二军医大学 | 一种糖肽类抗真菌化合物及其制备方法与应用 |
| US20150320675A1 (en) | 2013-01-18 | 2015-11-12 | University Of Utah Research Foundation | Modified Release Osmotic Pump for PH-Responsive Drug Delivery |
| WO2014124504A1 (en) | 2013-02-13 | 2014-08-21 | Katholieke Universiteit Leuven Ku Leuven Research & Development | Compositions and methods for treating biofilms |
| EP2968381A4 (en) | 2013-03-15 | 2016-11-30 | Sidney Hecht | Sugar-linker-drug conjugates |
| NZ713615A (en) | 2013-05-01 | 2020-05-29 | Neoculi Pty Ltd | Methods for treating bacterial infections |
| WO2015035102A2 (en) | 2013-09-04 | 2015-03-12 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of fungal infections |
| WO2017049105A1 (en) | 2015-09-16 | 2017-03-23 | Cidara Therapeutics, Inc. | Formulations for treating fungal infections |
| WO2017049102A1 (en) | 2015-09-16 | 2017-03-23 | Cidara Therapeutics, Inc. | Methods for treating fungal infections |
| HK1258533A1 (zh) | 2016-01-08 | 2019-11-15 | Cidara Therapeutics, Inc. | 防止和治疗肺孢子虫感染的方法 |
| MA43825A (fr) | 2016-03-16 | 2021-04-07 | Cidara Therapeutics Inc | Schémas posologiques pour le traitement d'infections fongiques |
| US20190307843A1 (en) | 2016-11-01 | 2019-10-10 | Cidara Therapeutics, Inc. | Single dose methods for preventing and treating fungal infections |
| US20210002346A1 (en) | 2016-11-29 | 2021-01-07 | Cidara Therapeutics, Inc | Methods for preventing fungal infections |
| EP3577129A1 (en) | 2017-01-31 | 2019-12-11 | Cidara Therapeutics, Inc. | Methods for treating fungal infections |
| WO2018187574A1 (en) | 2017-04-05 | 2018-10-11 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of fungal infections |
| WO2018191692A1 (en) | 2017-04-14 | 2018-10-18 | Cidara Therapeutics, Inc. | Methods for treating fungal infections |
| CA3069423C (en) | 2017-07-12 | 2025-04-15 | Napp Pharmaceutical Group Limited | Formulations for the treatment of fungal infections |
| US20200164023A1 (en) | 2017-08-03 | 2020-05-28 | Cidara Therapeutics, Inc. | Methods for preventing and treating intra-abdominal candidiasis |
| WO2019241626A1 (en) | 2018-06-15 | 2019-12-19 | Cidara Therapeutics, Inc. | Synthesis of echinocandin antifungal agent |
-
2012
- 2012-03-02 NO NO12751994A patent/NO2680873T3/no unknown
- 2012-03-02 CA CA 3053850 patent/CA3053850A1/en not_active Abandoned
- 2012-03-02 HR HRP20171579TT patent/HRP20171579T8/hr unknown
- 2012-03-02 SI SI201231096T patent/SI2680873T1/sl unknown
- 2012-03-02 EP EP17158336.2A patent/EP3192803B1/en active Active
- 2012-03-02 CN CN201610692359.9A patent/CN106279369B/zh active Active
- 2012-03-02 PL PL12751994T patent/PL2680873T3/pl unknown
- 2012-03-02 RS RS20171032A patent/RS56426B1/sr unknown
- 2012-03-02 DK DK12751994.0T patent/DK2680873T3/en active
- 2012-03-02 JP JP2013556894A patent/JP5809296B2/ja active Active
- 2012-03-02 HU HUE12751994A patent/HUE036778T2/hu unknown
- 2012-03-02 ES ES12751994.0T patent/ES2645074T3/es active Active
- 2012-03-02 PT PT127519940T patent/PT2680873T/pt unknown
- 2012-03-02 EP EP12751994.0A patent/EP2680873B1/en active Active
- 2012-03-02 LT LTEP12751994.0T patent/LT2680873T/lt unknown
- 2012-03-02 CA CA2865791A patent/CA2865791C/en active Active
- 2012-03-02 SM SM20170460T patent/SMT201700460T1/it unknown
- 2012-03-02 CN CN201280021321.9A patent/CN103889221B/zh active Active
- 2012-03-02 WO PCT/US2012/027451 patent/WO2012119065A2/en not_active Ceased
-
2013
- 2013-05-03 US US13/886,972 patent/US8722619B2/en active Active
-
2014
- 2014-04-01 US US14/242,192 patent/US9217014B2/en active Active
-
2015
- 2015-09-10 JP JP2015178029A patent/JP6111447B2/ja active Active
- 2015-11-24 US US14/950,801 patent/US9676821B2/en active Active
-
2017
- 2017-02-16 JP JP2017026954A patent/JP6302108B2/ja active Active
- 2017-05-18 US US15/598,913 patent/US20170253635A1/en not_active Abandoned
- 2017-10-23 CY CY20171101099T patent/CY1119709T1/el unknown
-
2018
- 2018-03-01 JP JP2018036159A patent/JP2018118977A/ja active Pending
-
2021
- 2021-07-01 US US17/365,188 patent/US12344680B2/en active Active
-
2024
- 2024-06-19 FI FIC20240022C patent/FIC20240022I1/fi unknown
- 2024-06-19 LT LTPA2024520C patent/LTPA2024520I1/lt unknown
- 2024-06-19 CY CY2024022C patent/CY2024022I2/el unknown
- 2024-06-20 HU HUS2400021C patent/HUS2400021I1/hu unknown
- 2024-06-20 FR FR24C1027C patent/FR24C1027I2/fr active Active
- 2024-06-21 NL NL301280C patent/NL301280I2/nl unknown
-
2025
- 2025-06-03 US US19/226,762 patent/US20250289852A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516339A5 (cg-RX-API-DMAC7.html) | ||
| JP5882260B2 (ja) | ペプチドおよびその使用 | |
| JP6824044B2 (ja) | 真菌感染症の治療方法 | |
| AU2017283785A1 (en) | Synergistic antifungal compositions and methods thereof | |
| US20170232004A1 (en) | Methods for treating fungal infections | |
| WO2012065079A4 (en) | Methods of treating cancer | |
| EP2707007B1 (en) | Antifungal compositions for the treatment of nails | |
| WO2018102407A1 (en) | Methods for preventing fungal infections | |
| CA2864910C (en) | Antifungal compositions for the treatment of skin and nails | |
| SA515361162B1 (ar) | تركيبة صيدلانية جديدة لعلاج العدوى الفطرية | |
| US20230364067A1 (en) | Antifungal agents with enhanced activity in acidic ph | |
| WO2016201283A1 (en) | Antifungal agents | |
| CN101522195B (zh) | 含有苯基脒衍生物的药物组合物和该药物组合物与抗真菌剂的联合使用方法 | |
| WO2008094912B1 (en) | Substituted gamma lactams as therapeutic agents | |
| JPWO2006109642A1 (ja) | 医薬組成物および抗真菌剤を組み合わせて使用する方法 | |
| CA2797783A1 (en) | Compounds for anti-fungal treatment | |
| CN113498343A (zh) | 用于治疗真菌性骨关节感染的三萜抗真菌剂 | |
| RU2012114097A (ru) | Терапевтический агент против хронической боли | |
| US20120004294A1 (en) | Antitumor combination combining ave8062 and docetaxel | |
| HK40091926A (en) | Antifungal agents with enhanced activity in acidic ph | |
| CL2023002361A1 (es) | Tratamientos del síndrome de prader-willi | |
| RU2024119558A (ru) | Композиции, содержащие порошок для ингаляций вориконазола, способы их изготовления и применения | |
| HK40030410B (en) | Antifungal agents with enhanced activity in acidic ph | |
| HK40030410A (en) | Antifungal agents with enhanced activity in acidic ph | |
| CN103356624A (zh) | 一种嘧啶类化合物在抗真菌药物中的应用 |